VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$3.29 USD
+0.10 (3.13%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $3.30 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for VistaGen Therapeutics, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 119 | 17 | 68 | 103 | 1 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 3 | 1 | 0 |
Total Current Assets | 121 | 18 | 71 | 104 | 2 |
Net Property & Equipment | 0 | 1 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 0 | 1 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 124 | 21 | 75 | 108 | 6 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 3 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 1 | 1 | 2 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 1 | 0 |
Total Current Liabilities | 5 | 5 | 6 | 4 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 3 | 2 | 2 | 2 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 6 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 9 | 10 | 16 | 12 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 474 | 343 | 336 | 316 | 200 |
Retained Earnings | -356 | -327 | -268 | -220 | -202 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 4 | 4 | 4 | 4 | 4 |
Total Shareholder's Equity | 114 | 12 | 65 | 92 | -6 |
Total Liabilities & Shareholder's Equity | 124 | 21 | 75 | 108 | 6 |
Total Common Equity | 114 | 12 | 65 | 92 | -6 |
Shares Outstanding | 27.00 | 7.30 | 6.80 | 6.00 | 1.60 |
Book Value Per Share | 4.23 | 1.65 | 9.52 | 15.33 | -3.58 |
Fiscal Year End for VistaGen Therapeutics, Inc falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 108 | 119 | 127 | 38 | 10 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 1 | 2 |
Total Current Assets | 111 | 121 | 128 | 39 | 12 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 1 | 0 | 1 | 1 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 114 | 124 | 131 | 42 | 15 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 1 |
Accounts Payable | 1 | 2 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 1 | 2 | 1 | 1 |
Total Current Liabilities | 6 | 5 | 4 | 3 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 3 | 2 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 9 | 8 | 7 | 8 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 476 | 474 | 474 | 380 | 345 |
Retained Earnings | -367 | -356 | -347 | -340 | -334 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 4 | 4 | 4 | 4 | 4 |
Total Shareholder's Equity | 105 | 114 | 123 | 36 | 7 |
Total Liabilities & Shareholder's Equity | 114 | 124 | 131 | 42 | 15 |
Total Common Equity | 105 | 114 | 123 | 36 | 7 |
Shares Outstanding | 27.00 | 27.00 | 27.00 | 12.00 | 7.90 |
Book Value Per Share | 3.88 | 4.23 | 4.57 | 2.97 | 0.87 |